ReviewJournal of enzyme inhibition and medicinal chemistry2026
Recent progress in small molecules targeting the acidic tumor microenvironment.
Review in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acidic tumour microenvironment (pHe 6.5-6.9) is sustained by the Warburg effect and pH regulators, such as monocarboxylate transporters 1 and 4, Na+/H + exchanger 1, vacuolar ATPase, and carbonic anhydrases IX and XII. This environment facilitates tumour invasion, immune evasion, and resistance to therapy in solid tumours. Recent advancements in small molecule inhibitors targeting these pathways have demonstrated potential in molecular design, mechanisms of action, and preclinical studies. However, practical applications face challenges, including metabolic compensation, insufficient target selectivity, and clinical translation difficulties. This article reviews the structural design, structure-activity relationships, biological activity, and clinical trial progress of small molecule inhibitors. It also summarises acid-targeted delivery strategies, such as pH-responsive prodrugs and pHLIP peptides. The aim is to highlight the opportunities and challenges in acid-base regulation within the tumour microenvironment and offer insights for developing a new generation of antitumor drugs with high selectivity and low toxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.